Publications by authors named "Daniel Guthy"

Claim this Profile
I
Identification and characterization of binders to a cryptic and functional pocket in KRAS.
Kim S Beyer, Jessica Klein, Stéphanie Katz, Patrick Welker, Mylene Lanter, Daniel Guthy

Nat Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Targeting the SHOC2-RAS interaction in RAS-mutant cancers.
Zachary J Hauseman, Frédéric Stauffer, Kim S Beyer, Sandra Mollé, Elena Cavicchioli, Daniel A Guthy

Nature· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Promise and Challenge of β-Lactone Electrophiles to Target Aspartate 12 of Mutant KRAS.
Balázs Budai, Andrea Vaupel, Callum J Dickson, Kim S Beyer, Daniel A Guthy

J Med Chem· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the SHOC2-RAS interaction in RAS-mutant cancers.
Zachary J Hauseman, Frédéric Stauffer, Kim S Beyer, Sandra Mollé, Elena Cavicchioli, Daniel A Guthy

Nature· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reversible Small Molecule Multivariant Ras Inhibitors Display Tunable Affinity for the Active and Inactive Forms of Ras.
Charles W Parry, Francesca Pellicano, Alexander W Schüttelkopf, Kim S Beyer, Justin Bower, Daniel A Guthy

J Med Chem· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, Synthesis, and In Vitro and In Vivo Evaluation of Cereblon Binding Bruton's Tyrosine Kinase (BTK) Degrader CD79b Targeted Antibody-Drug Conjugates.
Alan Zhang, Katherine Seiss, Laurent Laborde, Sebastian Palacio-Ramirez, Daniel Guthy

Bioconjug Chem· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRAS for the Treatment of Solid Tumors.
Edwige Lorthiois, Marc Gerspacher, Kim S Beyer, Andrea Vaupel, Catherine Leblanc, Daniel A Guthy

J Med Chem· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.
Andreas Weiss, Edwige Lorthiois, Louise Barys, Kim S Beyer, Claudio Bomio-Confaglia, Daniel Alexander Guthy

Cancer Discov· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor.
Robin A Fairhurst, Pascal Furet, Patricia Imbach-Weese, Frédéric Stauffer, Heinrich Rueeger, Daniel A Guthy

J Med Chem· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EndoBind detects endogenous protein-protein interactions in real time.
Anke Bill, Sheryll Espinola, Daniel Guthy, Jacob R Haling, Mylene Lanter

Commun Biol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New Potent DOT1L Inhibitors for Evaluation in Mouse.
Frédéric Stauffer, Andreas Weiss, Clemens Scheufler, Henrik Möbitz, Christian Ragot, Daniel Guthy

ACS Med Chem Lett· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous low plasma concentrations of everolimus provides equivalent efficacy to oral daily dosing in mouse xenograft models of human cancer.
Laurent Laborde, Fatos Oz, Mitko Ristov, Daniel Guthy, Dario Sterker

Cancer Chemother Pharmacol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.
Sébastien Jeay, Swann Gaulis, Stéphane Ferretti, Hans Bitter, Moriko Ito, Daniel A Guthy

Elife· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach.
Chao Chen, Hugh Zhu, Frédéric Stauffer, Giorgio Caravatti, Susanne Vollmer, Daniel Guthy

ACS Med Chem Lett· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.
Barbara Herkert, Audrey Kauffmann, Sandra Mollé, Christian Schnell, Thomas Ferrat, Daniel Guthy

Cancer Res· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a novel tricyclic 4H-thiazolo[5',4':4,5]pyrano[2,3-c]pyridine-2-amino scaffold and its application in a PI3Kα inhibitor with high PI3K isoform selectivity and potent cellular activity.
Marc Gerspacher, Robin A Fairhurst, Robert Mah, Esther Roehn-Carnemolla, Pascal Furet, Daniel A Guthy

Bioorg Med Chem Lett· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and optimisation of 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole and 4,5-dihydrothiazolo[4,5-h]quinazoline series of selective phosphatidylinositol-3 kinase alpha inhibitors.
Robin A Fairhurst, Marc Gerspacher, Patricia Imbach-Weese, Robert Mah, Giorgio Caravatti, Daniel A Guthy

Bioorg Med Chem Lett· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and optimisation of a 4',5-bisthiazole series of selective phosphatidylinositol-3 kinase alpha inhibitors.
Robin A Fairhurst, Patricia Imbach-Weese, Marc Gerspacher, Giorgio Caravatti, Pascal Furet, Daniel A Guthy

Bioorg Med Chem Lett· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.
Sébastien Jeay, Swann Gaulis, Stéphane Ferretti, Hans Bitter, Moriko Ito, Daniel A Guthy

Elife· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.
Christine Fritsch, Alan Huang, Christian Chatenay-Rivauday, Christian Schnell, Anupama Reddy, Daniel Guthy

Mol Cancer Ther· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations.
Saskia M Brachmann, Julia Kleylein-Sohn, Swann Gaulis, Audrey Kauffmann, Marcel J J Blommers, Daniel Alexander Guthy

Mol Cancer Ther· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.
Sauveur-Michel Maira, Sabina Pecchi, Alan Huang, Matthew Burger, Mark Knapp, Daniel Guthy

Mol Cancer Ther· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival.
Joëlle Rubert, Zhiyan Qian, Rita Andraos, Daniel A Guthy, Thomas Radimerski

BMC Cancer· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of drug resistance by artificial transcription factors.
Pilar Blancafort, Mario P Tschan, Sharon Bergquist, Daniel Guthy, Arndt Brachat

Mol Cancer Ther· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic reprogramming of tumor cells by zinc finger transcription factors.
Pilar Blancafort, Emily I Chen, Beatriz Gonzalez, Sharon Bergquist, Andries Zijlstra, Daniel Guthy

Proc Natl Acad Sci U S A· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis